首页> 外国专利> P22 - PMAP36 ETEC The composition of the enterotoxigenic Escherichia coli ghost vaccine candidate by recombinant P22 lysozyme-PMAP36 fusion protein against neonatal piglet colibacillosis

P22 - PMAP36 ETEC The composition of the enterotoxigenic Escherichia coli ghost vaccine candidate by recombinant P22 lysozyme-PMAP36 fusion protein against neonatal piglet colibacillosis

机译:P22-PMAP36 ETEC重组P22溶菌酶-PMAP36融合蛋白抗新生仔猪大肠杆菌病的产肠毒素大肠杆菌幽灵疫苗的组成。

摘要

The present invention relates to an enterotoxigenic excherichia coil (ETEC) ghost vaccine composition using a recombinant p22 lysozyme-PMAP36 fusion protein for preventing colibacillosis of a weaning pig. ETEC strains expressing F4 and F18 fimbria are induced to be ghost by a p22 lysozyme-PMAP36 fusion protein, and an effect of induced cells as an ETEC ghost vaccine is evaluated. In order to evaluate the efficacy of a new preventive vaccine candidate material, the preventive vaccine candidate material is intramuscularly inoculated to a weaning piglet, and the resistance to colibacillosis after weaning is confirmed. In other words, each fimbria-containing ghost vaccine is intramuscularly inoculated to the piglet of a group B at 2 weeks after birth to have 2×10^9 cells, and a PBS is intramuscularly inoculated to weaning piglet of a control group A. The titer of serum IgG of the piglet of the group B is significantly increased compared to that of an antibody of the piglet of the group A. After, the piglet is infected by a wild-type ETET, the diarrhea and mortality are not observed in all piglets of the group B but a diarrhea symptom is observed in 70% of the piglets of the group A, and 30% of a mortality rate is shown therein. Accordingly, enterotoxigenic colibacillosis after weaning is confirmed to be effectively resisted when a newly prepared vaccine is intramuscularly inoculated to the weaning piglet.
机译:用于预防断奶仔猪大肠杆菌病的重组p22溶菌酶-PMAP36融合蛋白技术领域本发明涉及一种肠毒素致病性埃希氏菌(ETEC)幽灵疫苗组合物,其使用重组p22溶菌酶-PMAP36融合蛋白来预防断奶猪大肠杆菌病。通过p22溶菌酶-PMAP36融合蛋白将表达F4和F18菌毛的ETEC菌株诱导为幽灵,并评价诱导细胞作为ETEC幽灵疫苗的作用。为了评估新的预防性疫苗候选物材料的功效,将预防性疫苗候选物材料肌内接种至断奶仔猪,并确认对断奶后的大肠杆菌病具有抗性。换句话说,每只含菌毛的幽灵疫苗在出生后2周肌肉注射到B组的仔猪中,使其具有2×10 ^ 9细胞,而PBS肌肉注射到对照组A的断奶仔猪。与A组仔猪的抗体相比,B组仔猪的血清IgG滴度显着增加。之后,该猪被野生型ETET感染,没有观察到腹泻和死亡率。 B组的仔猪,但在A组的仔猪中观察到腹泻症状70%,其中显示出30%的死亡率。因此,当将新制备的疫苗肌肉内接种到断奶仔猪中时,断奶后的肠毒素性大肠杆菌病被证实能有效抵抗。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号